Holen Sie sich die Stockscreener-App
3.34
0.00%
0.00
Schlusskurs vom Vortag:
$3.34
Offen:
$3.35
24-Stunden-Volumen:
271.15K
Relative Volume:
0.35
Marktkapitalisierung:
$142.61M
Einnahmen:
$20.72M
Nettoeinkommen (Verlust:
$-100.84M
KGV:
-1.2556
EPS:
-2.66
Netto-Cashflow:
$-78.56M
1W Leistung:
+8.44%
1M Leistung:
-7.99%
6M Leistung:
-61.03%
1J Leistung:
-85.63%
1-Tages-Spanne:
$3.24
$3.46
1-Wochen-Bereich:
$3.11
$3.74
52-Wochen-Spanne:
$2.235
$28.93
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Firmenname
4 D Molecular Therapeutics Inc
Sektor
Branche
Telefon
(510) 505-2680
Adresse
5858 HORTON STREET #455, EMERYVILLE
Vergleichen Sie FDMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
3.34 | 142.61M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-13 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Underweight |
| 2024-09-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | Eingeleitet | Barclays | Overweight |
| 2024-02-07 | Fortgesetzt | Goldman | Buy |
| 2023-10-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-18 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-11-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-11-15 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-12 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | Eingeleitet | Jefferies | Buy |
| 2022-01-04 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | BofA Securities | Buy |
| 2021-01-05 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-05 | Eingeleitet | Goldman | Neutral |
Alle ansehen
4 D Molecular Therapeutics Inc Aktie (FDMT) Neueste Nachrichten
X-linked retinitis pigmentosa Pipeline Analysis and Clinical - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Geode Capital Management LLC - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given Sell (E+) Rating at Weiss Ratings - Defense World
4D Molecular Therapeutics Inc [FDMT] Shares Rise 0.59 % on Wednesday - knoxdaily.com
Retinitis Pigmentosa Drugs Market 2034: EMA, PDMA, FDA Approvals Clinical Trials, Prevalence, Medication, Revenue, Statistics, Pipeline and Companies by DelveInsight - The Globe and Mail
American Express Just Delivered Fantastic News for Investors. Here's Why the Warren Buffett Stock Is a Buy Now. - The Globe and Mail
Orion Mine Finance selling at Allied Gold (AAUC) - The Globe and Mail
How should investors view 4D Molecular Therapeutics Inc (FDMT)? - uspostnews.com
Discover Fractyl Health And 2 More Promising Penny Stocks - simplywall.st
Analyzing 4D Molecular Therapeutics (NASDAQ:FDMT) & Gilead Sciences (NASDAQ:GILD) - Defense World
JPMorgan Chase & Co. Raises Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
What is Leerink Partnrs’ Estimate for FDMT FY2026 Earnings? - Defense World
Vanguard Group Inc. Boosts Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Retinitis Pigmentosa Market Growth to Accelerate in Forecast - openPR.com
Retinitis Pigmentosa Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics - Barchart.com
American Century Companies Inc. Acquires 4,429 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Wellington Management Group LLP Purchases 11,089 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
8,600 Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Acquired by KLP Kapitalforvaltning AS - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Rating of “Moderate Buy” by Analysts - Defense World
4DMT Announces New Employment Inducement Grants - GlobeNewswire
4D Molecular Therapeutics, Inc. (FDMT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates - ACCESS Newswire
Weiss Ratings Reaffirms Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
Raymond James Financial Inc. Takes Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics stock hits 52-week low at $3.46 - Investing.com India
4D Molecular Therapeutics stock hits 52-week low at $3.46 By Investing.com - Investing.com South Africa
Charles Schwab Investment Management Inc. Sells 29,708 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
PNC Financial Services Group Inc. Raises Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4DMT to Participate in Upcoming Investor Conferences - GlobeNewswire
Here Is How Powerful 4D Molecular Therapeutics Inc (NASDAQ: FDMT) Stock Is - Stocks Register
Connor Clark & Lunn Investment Management Ltd. Raises Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Weiss Ratings Reiterates Sell (E+) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - The AM Reporter
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Down 15.1% in February - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $30.63 Average PT from Analysts - The AM Reporter
Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) PT at $30.63 - Defense World
M&T Bank Corp Boosts Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Proficio Capital Partners LLC Has $111,000 Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics’ SWOT analysis: gene therapy firm faces durability hurdles - Investing.com
Are CytomX Therapeutics Inc (CTMX) shares a good deal now? - US Post News
4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Cut to $40.00 by Analysts at Bank of America - Defense World
4DMT enrolls first patient in late-stage trial for its retinal eye disease therapy -March 10, 2025 at 09:31 am EDT - Marketscreener.com
4D Molecular announces first patients enrolled in 4FRONT-1 Phase 3 trial - TipRanks
4D Molecular Therapeutics Enrolls First Patients in Phase 3 Clinical Trial for 4D-150, Targeting Wet Age-Related Macular Degeneration - Nasdaq
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD - GlobeNewswire
4D Molecular Launches Pivotal Phase 3 Trial for Revolutionary Eye Treatment - StockTitan
Rhumbline Advisers Acquires 3,675 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by New York State Common Retirement Fund - Defense World
FY2025 EPS Estimates for FDMT Boosted by Cantor Fitzgerald - Defense World
Finanzdaten der 4 D Molecular Therapeutics Inc-Aktie (FDMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):